Luc Guillaume, Gronnier Caroline, Lebreton Gil, Brigand Cecile, Mabrut Jean-Yves, Bail Jean-Pierre, Meunier Bernard, Collet Denis, Mariette Christophe
Department of Digestive Surgery, Haut Lévèque University Hospital, Bordeaux, France.
Inserm, Unit 1026, University of Bordeaux, Bordeaux, France.
Ann Surg Oncol. 2015 Dec;22 Suppl 3:S1357-64. doi: 10.1245/s10434-015-4619-8. Epub 2015 May 27.
Minimal data have previously emerged from studies regarding the factors associated with recurrence in patients with ypT0N0M0 status. The purpose of the study was to predict survival and recurrence in patients with pathological complete response (pCR) following chemoradiotherapy (CRT) and surgery for esophageal cancer (EC).
Among 2944 consecutive patients with EC operations in 30 centers between 2000 and 2010, patients treated with neoadjuvant CRT followed by surgery who achieved pCR (n = 191) were analyzed. The factors associated with survival and recurrence were analyzed using a Cox proportional hazard regression analysis.
Among 593 patients who underwent neoadjuvant CRT followed by esophagectomy, pCR was observed in 191 patients (32.2 %). Recurrence occurred in 56 (29.3 %) patients. The median time to recurrence was 12 months. The factors associated with recurrence were postoperative complications grade 3-4 [odds ratio (OR): 2.100; 95 % confidence interval (CI) 1.008-4.366; p = 0.048) and adenocarcinoma histologic subtype (OR 2.008; 95 % CI 0.1.06-0.3.80; p = 0.032). The median overall survival was 63 months (95 % CI 39.3-87.1), and the median disease-free survival was 48 months (95 % CI 18.3-77.4). Age (>65 years) [hazard ratio (HR): 2.166; 95 % CI 1.170-4.010; p = 0.014), postoperative complications grades 3-4 [HR 2.099; 95 % CI 1.137-3.878; p = 0.018], and radiation dose (<40 Gy) (HR 0.361; 95 % CI 0.159-0.820; p = 0.015) were identified as factors associated with survival.
An intensive follow-up may be beneficial for patients with EC who achieve pCR and who develop major postoperative complications or the adenocarcinoma histologic subtype.
关于ypT0N0M0状态患者复发相关因素的研究此前仅有极少数据。本研究旨在预测接受食管癌放化疗(CRT)及手术治疗后达到病理完全缓解(pCR)患者的生存及复发情况。
在2000年至2010年间30个中心连续接受食管癌手术的2944例患者中,分析接受新辅助CRT后手术且达到pCR的患者(n = 191)。采用Cox比例风险回归分析生存及复发的相关因素。
在593例接受新辅助CRT后行食管切除术的患者中,191例(32.2%)达到pCR。56例(29.3%)患者出现复发。复发的中位时间为12个月。与复发相关的因素为3 - 4级术后并发症[比值比(OR):2.100;95%置信区间(CI)1.008 - 4.366;p = 0.048]和腺癌组织学亚型(OR 2.008;95% CI 1.06 - 3.80;p = 0.032)。中位总生存期为63个月(95% CI 39.3 - 87.1),中位无病生存期为48个月(95% CI 18.3 - 77.4)。年龄(>65岁)[风险比(HR):2.166;95% CI 1.170 - 4.010;p = 0.014]、3 - 4级术后并发症[HR 2.099;95% CI 1.137 - 3.878;p = 0.018]及放疗剂量(<40 Gy)(HR 0.361;95% CI 0.159 - 0.820;p = 0.015)被确定为与生存相关的因素。
对于达到pCR且出现严重术后并发症或腺癌组织学亚型的食管癌患者,加强随访可能有益。